Found: 89
Select item for more details and to access through your institution.
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1587, doi. 10.1007/s10637-021-01141-2
- By:
- Publication type:
- Article
A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 6, p. 1774, doi. 10.1007/s10637-020-00928-z
- By:
- Publication type:
- Article
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 6, p. 1016, doi. 10.1007/s10637-018-0591-z
- By:
- Publication type:
- Article
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck.
- Published in:
- Investigational New Drugs, 2008, v. 26, n. 3, p. 257, doi. 10.1007/s10637-007-9098-8
- By:
- Publication type:
- Article
Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies.
- Published in:
- Investigational New Drugs, 2005, v. 23, n. 5, p. 455, doi. 10.1007/s10637-005-2905-1
- By:
- Publication type:
- Article
Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy.
- Published in:
- Cell Death & Disease, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41419-022-05548-4
- By:
- Publication type:
- Article
Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer.
- Published in:
- Clinical Colorectal Cancer, 2023, v. 22, n. 4, p. 457, doi. 10.1016/j.clcc.2023.08.006
- By:
- Publication type:
- Article
Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer.
- Published in:
- Clinical Colorectal Cancer, 2021, v. 20, n. 4, p. 334, doi. 10.1016/j.clcc.2021.07.004
- By:
- Publication type:
- Article
Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Cancer patients’ acceptability of incorporating an epidemiology questionnaire within a clinical trial.
- Published in:
- 2015
- By:
- Publication type:
- Journal Article
Cancer patients’ acceptability of incorporating an epidemiology questionnaire within a clinical trial.
- Published in:
- Clinical Trials, 2015, v. 12, n. 3, p. 237, doi. 10.1177/1740774514568689
- By:
- Publication type:
- Article
Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor.
- Published in:
- Genome Medicine, 2020, v. 12, n. 1, p. 1, doi. 10.1186/s13073-020-00730-9
- By:
- Publication type:
- Article
Molecular profiling for precision cancer therapies.
- Published in:
- Genome Medicine, 2020, v. 12, n. 1, p. 1, doi. 10.1186/s13073-019-0703-1
- By:
- Publication type:
- Article
Designing circulating tumor DNA-based interventional clinical trials in oncology.
- Published in:
- Genome Medicine, 2019, v. 11, n. 1, p. N.PAG, doi. 10.1186/s13073-019-0634-x
- By:
- Publication type:
- Article
Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care.
- Published in:
- European Journal of Human Genetics, 2014, v. 22, n. 3, p. 391, doi. 10.1038/ejhg.2013.158
- By:
- Publication type:
- Article
Response: Re: Dose Escalation Methods in Phase I Cancer Clinical Trials.
- Published in:
- 2009
- By:
- Publication type:
- Letter
Dose Escalation Methods in Phase I Cancer Clinical Trials.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2009, v. 101, n. 10, p. 708, doi. 10.1093/jnci/djp079
- By:
- Publication type:
- Article
Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2022, v. 41, n. 1, p. 1, doi. 10.1186/s13046-021-02236-7
- By:
- Publication type:
- Article
Prospective manipulation of the gut microbiome with microbial ecosystem therapeutic 4 (MET4) in HPV-related locoregionally-advanced oropharyngeal cancer squamous cell carcinoma (LA-OPSCC) undergoing primary chemoradiation: ROMA2 study.
- Published in:
- British Journal of Cancer, 2024, v. 130, n. 12, p. 1936, doi. 10.1038/s41416-024-02701-y
- By:
- Publication type:
- Article
A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events.
- Published in:
- British Journal of Cancer, 2023, v. 129, n. 4, p. 612, doi. 10.1038/s41416-023-02307-w
- By:
- Publication type:
- Article
Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study).
- Published in:
- 2021
- By:
- Publication type:
- journal article
Increasing operational and scientific efficiency in clinical trials.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 168, n. 1, p. 159, doi. 10.1007/s10549-017-4580-2
- By:
- Publication type:
- Article
Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Epstein-Barr Virus DNA Measured in Nasopharyngeal Brushings in Patients with Nasopharyngeal Carcinoma: Pilot Study.
- Published in:
- Journal of Otolaryngology, 2004, v. 33, n. 5, p. 299, doi. 10.2310/7070.2004.00299
- By:
- Publication type:
- Article
Early phase clinical trials to identify optimal dosing and safety.
- Published in:
- Molecular Oncology, 2015, v. 9, n. 5, p. 997, doi. 10.1016/j.molonc.2014.07.025
- By:
- Publication type:
- Article
Precision cancer medicine: Concepts, current practice, and future developments.
- Published in:
- Journal of Internal Medicine, 2023, v. 294, n. 4, p. 455, doi. 10.1111/joim.13709
- By:
- Publication type:
- Article
Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer.
- Published in:
- Oncologist, 2023, v. 28, n. 12, p. e1209, doi. 10.1093/oncolo/oyad210
- By:
- Publication type:
- Article
Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. 352, doi. 10.1093/oncolo/oyac047
- By:
- Publication type:
- Article
Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials.
- Published in:
- Oncologist, 2022, v. 27, n. 3, p. e286, doi. 10.1093/oncolo/oyac020
- By:
- Publication type:
- Article
Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era.
- Published in:
- Oncologist, 2019, v. 24, n. 7, p. e518, doi. 10.1634/theoncologist.2018-0808
- By:
- Publication type:
- Article
Feasibility Assessment of Using the Complete Patient‐Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO‐CTCAE) Item Library.
- Published in:
- Oncologist, 2019, v. 24, n. 4, p. e146, doi. 10.1634/theoncologist.2018-0332
- By:
- Publication type:
- Article
Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials.
- Published in:
- Oncologist, 2015, v. 20, n. 6, p. 653, doi. 10.1634/theoncologist.2015-0008
- By:
- Publication type:
- Article
The Utility of Hedgehog Signaling Pathway Inhibition for Cancer.
- Published in:
- Oncologist, 2012, v. 17, n. 8, p. 1090, doi. 10.1634/theoncologist.2011-0450
- By:
- Publication type:
- Article
Cancer patients' experiences with immune checkpoint modulators: A qualitative study.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 9, p. 3015, doi. 10.1002/cam4.2940
- By:
- Publication type:
- Article
Fc‐gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.
- Published in:
- Cancer Medicine, 2018, v. 7, n. 11, p. 5478, doi. 10.1002/cam4.1819
- By:
- Publication type:
- Article
Pre-Clinical Characterization of Dacomitinib (PF-00299804), an Irreversible Pan-ErbB Inhibitor, Combined with Ionizing Radiation for Head and Neck Squamous Cell Carcinoma.
- Published in:
- PLoS ONE, 2014, v. 9, n. 5, p. 1, doi. 10.1371/journal.pone.0098557
- By:
- Publication type:
- Article
Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 10, p. 1620, doi. 10.1002/cncr.33378
- By:
- Publication type:
- Article
Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin.
- Published in:
- Cancer (0008543X), 2020, v. 126, n. 22, p. 4936, doi. 10.1002/cncr.33145
- By:
- Publication type:
- Article
Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities.
- Published in:
- Cancer (0008543X), 2019, v. 125, n. 8, p. 1341, doi. 10.1002/cncr.31999
- By:
- Publication type:
- Article
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 3, p. 380, doi. 10.1007/s10637-022-01326-3
- By:
- Publication type:
- Article
Tumour heterogeneity in the clinic.
- Published in:
- Nature, 2013, v. 501, n. 7467, p. 355, doi. 10.1038/nature12627
- By:
- Publication type:
- Article
Precision Medicine in Head and Neck Cancer: Myth or Reality?
- Published in:
- Clinical Medicine Insights: Oncology, 2018, n. 12, p. 1, doi. 10.1177/1179554918779581
- By:
- Publication type:
- Article